What is the latest market price of zotuximab (Vyloy) in 2025

Zolbetuximab (zolbetuximab)-VYLOY is a humanized monoclonal antibody drug targeting the CLDN18.2 target, which is highly expressed in some gastric cancers and gastroesophageal junction adenocarcinoma cells. It binds to the CLDN18.2 protein on the surface of tumor cells, triggering antibody-dependent cytotoxicity of the immune system, thereby selectively killing cancer cells. Because its mechanism is highly specific, it has received increasing attention in the era of precision medicine. For people with advanced gastric cancer for whom traditional chemotherapy has limited effects, the emergence of zotuximab has brought new targeted treatment options to the clinic.

Currently, the original drug of zotuximab has been officially launched in China under the trade name "Weiluoyi", but it has not yet been included in the national medical insurance catalog, so patients mostly need to pay for the actual medication themselves. According to public information in overseas markets, original research is available in Europe and Japan, and the specification is 100mg injection form. The price fluctuates to a certain extent due to regional differences and exchange rate changes. When converted into RMB, it is about 7,000 yuan per box. Compared with some gastric cancer targeted drugs that have been included in domestic medical insurance, the cost burden of zotuximab is still relatively high, which is also one of the practical issues that patients and clinicians are currently paying attention to. It is worth mentioning that there are no generics or biosimilars of this drug yet, so market competition is limited and price reductions are unlikely in the short term.

In terms of clinical application, zotuximab is mainly used for patients with CLDN18.2-positive, HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma. It is usually used in combination with chemotherapy, and its efficacy is better than chemotherapy alone. As international clinical guidelines are gradually updated, the drug is increasingly being included in first-line treatment options. For domestic patients, although price is still the core factor limiting its widespread application, with policy promotion and the possibility of future medical insurance negotiations, the threshold for use is expected to gradually decrease.

Reference materials:https://www.astellas.com/en/news/29401